Key statistics
On Monday, Aligos Therapeutics Inc (ALGS:NAQ) closed at 6.97, 85.24% above the 52 week low of 3.76 set on Apr 11, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 6.88 |
|---|---|
| High | 7.08 |
| Low | 6.31 |
| Bid | 6.66 |
| Offer | 7.09 |
| Previous close | 7.03 |
| Average volume | 34.43k |
|---|---|
| Shares outstanding | 6.15m |
| Free float | 4.80m |
| P/E (TTM) | -- |
| Market cap | 43.26m USD |
| EPS (TTM) | -12.70 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
- Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aligos Therapeutics Presents Positive Data at HEP-DART 2025
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
- Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
More ▼
